Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01958931 · ClinicalTrials.gov registry record
Evaluate the Utility of the ProLung Test as Adjunctive to CT Scan in the Diagnosis of Lung Cancer
A clinical trial, sponsored by Fresh Medical Laboratories.
- Completed
- Registry status
- 55
- Enrollment target
NCT01958931: Completed study, sponsored by Fresh Medical Laboratories.
NCT01958931 is a clinical trial that has completed, run by Fresh Medical Laboratories. The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01958931 has completed, sponsored by Fresh Medical Laboratories.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
Study Summary
A Study to evaluate the utility of the ProLung Test as an adjunct to CT scan in the diagnosis of lung cancer.
Primary Outcome
This Study will assess the stability of the ProLung Test classification algorithm when used as an adjunct to CT scan to determine whether it is appropriate to be used in a pivotal study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2007-09 |
| Est. Completion | 2011-01 |
What the finished NCT01958931 record still lists
NCT01958931 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01958931 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01958931 about?
NCT01958931 is a clinical study titled "Evaluate the Utility of the ProLung Test as Adjunctive to CT Scan in the Diagnosis of Lung Cancer". A Study to evaluate the utility of the ProLung Test as an adjunct to CT scan in the diagnosis of lung cancer.
What is the current status of trial NCT01958931?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2007-09. Estimated completion is 2011-01.
Who is sponsoring clinical trial NCT01958931?
This trial is sponsored by Fresh Medical Laboratories, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia